3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Magnetic Resonance Spectroscopy
8
X-Rays
7
Specimen Handling
7
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Biopsy
5
ulixertinib
3
trametinib
3
palbociclib
3
larotrectinib
3
erdafitinib
3
Temozolomide
3
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
ensartinib
2
dabrafenib
2
Vemurafenib
2
Topotecan
2
Paclitaxel
2
Nivolumab
2
Lomustine
2
LY3023414
2
Gemcitabine
2
Filgrastim
2
varlilumab
1
trastuzumab biosimilar HLX02
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
bempegaldesleukin
×
Lymphoid
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts